Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 22;22(1):27.
doi: 10.3390/ijms22010027.

miR-205 in Breast Cancer: State of the Art

Ilaria Plantamura  1 , Alessandra Cataldo  1 , Giulia Cosentino  1 , Marilena V Iorio  1
Affiliations
Review

miR-205 in Breast Cancer: State of the Art

Ilaria Plantamura et al. Int J Mol Sci. .

Abstract

Despite its controversial roles in different cancer types, miR-205 has been mainly described as an oncosuppressive microRNA (miRNA), with some contrasting results, in breast cancer. The role of miR-205 in the occurrence or progression of breast cancer has been extensively studied since the first evidence of its aberrant expression in tumor tissues versus normal counterparts. To date, it is known that the expression of miR-205 in the different subtypes of breast cancer is decreasing from the less aggressive subtype, estrogen receptor/progesterone receptor positive breast cancer, to the more aggressive, triple negative breast cancer, influencing metastasis capability, response to therapy and patient survival. In this review, we summarize the most important discoveries that have highlighted the functional role of this miRNA in breast cancer initiation and progression, in stemness maintenance, in the tumor microenvironment, its potential role as a biomarker and its relevance in normal breast physiology-the still open questions. Finally, emerging evidence reveals the role of some lncRNAs in breast cancer progression as sponges of miR-205. Here, we also reviewed the studies in this field.

Keywords: breast cancer; miR-205; oncogenic pathways; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of miR-205 oncosuppressive activity in breast cancer (created with BioRender.com).
See this image and copyright information in PMC

References

    1. Xiao Y., Humphries B., Yang C., Wang Z. MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019;5:53. doi: 10.3390/ncrna5040053. - DOI - PMC - PubMed
    1. Sørlie T., Wang Y., Xiao C., Johnsen H., Naume B., Samaha R.R., Børresen-Dale A.-L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms. BMC Genom. 2006;7:127. doi: 10.1186/1471-2164-7-127. - DOI - PMC - PubMed
    1. Iorio M.V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070. doi: 10.1158/0008-5472.CAN-05-1783. - DOI - PubMed
    1. Sempere L.F., Christensen M., Silahtaroglu A., Bak M., Heath C.V., Schwartz G., Wells W., Kauppinen S., Cole C.N. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–11620. doi: 10.1158/0008-5472.CAN-07-5019. - DOI - PubMed
    1. Sun E.-H., Zhou Q., Liu K.-S., Wei W., Wang C.-M., Liu X.-F., Lu C., Ma D.-Y. Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur. Rev. Med. Pharmacol. Sci. 2014;18:2783–2788. - PubMed

MeSH terms